Holen Sie sich die Stockscreener-App
16.82
0.24%
-0.04
Handel nachbörslich:
16.83
0.010
+0.06%
Schlusskurs vom Vortag:
$16.86
Offen:
$16.99
24-Stunden-Volumen:
945.50K
Relative Volume:
1.16
Marktkapitalisierung:
$683.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.05M
KGV:
-3.2788
EPS:
-5.13
Netto-Cashflow:
$-146.15M
1W Leistung:
-2.77%
1M Leistung:
+10.73%
6M Leistung:
+18.95%
1J Leistung:
-68.93%
1-Tages-Spanne:
$16.78
$18.42
1-Wochen-Bereich:
$16.31
$18.42
52-Wochen-Spanne:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Vergleichen Sie KROS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
16.82 | 513.66M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics announces final results of tender offer - MarketScreener
Keros Therapeutics (Nasdaq: KROS) completes $194M tender offer, buying 35.9% of shares - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - MarketScreener
Keros Therapeutics (Nasdaq: KROS) to Repurchase 10.95M Shares for $194.4M in Tender Offer - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
How to manage a losing position in Keros Therapeutics Inc.Portfolio Value Report & Free Accurate Trade Setup Notifications - newser.com
How to recover losses in Keros Therapeutics Inc. stockJuly 2025 Price Swings & Accurate Trade Setup Notifications - newser.com
Los Angeles Capital Management LLC Purchases New Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Is Keros Therapeutics Inc. stock attractive for income investors2025 Buyback Activity & Reliable Entry Point Alerts - newser.com
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Keros Therapeutics, Inc. $KROS - MarketBeat
Will Keros Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Summary & Daily Chart Pattern Signals - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Will Keros Therapeutics Inc. price bounce be sustainable2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Evaluating Keros Therapeutics Inc. with trendline analysisEntry Point & Short-Term Trading Opportunity Alerts - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.July 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Will Keros Therapeutics Inc. stock return to pre crisis levelsJuly 2025 Short Interest & Weekly Top Gainers Alerts - newser.com
Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat
Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq
Oppenheimer Adjusts Keros Therapeutics Price Target to $27 From $23, Maintains Outperform Rating - MarketScreener
Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq
KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus
Keros Therapeutics Drives Nasdaq Composite Momentum In Medicine - Kalkine Media
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - sharewise.com
How interest rate cuts could boost Keros Therapeutics Inc. stockDay Trade & AI Enhanced Execution Alerts - newser.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - sharewise.com
Why Keros Therapeutics Inc. stock remains undervaluedJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
What is HC Wainwright's Estimate for KROS FY2025 Earnings? - MarketBeat
FY2025 EPS Estimate for Keros Therapeutics Lifted by Analyst - MarketBeat
FY2025 EPS Forecast for Keros Therapeutics Raised by Analyst - MarketBeat
Will Keros Therapeutics Inc. stock deliver consistent dividendsWeekly Profit Recap & Verified Technical Trade Signals - newser.com
Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - news.stocktradersdaily.com
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):